Commentary  by Jonas, Richard A.
The previous two articles emphasize the very important
risks associated with placement of central venous catheters in
neonates and young infants. In the report by Lambert and
associates, placement of a Broviac catheter in the superior
vena cava in a premature infant resulted in thromboembolism
into the pulmonary artery tree. This necessitated a throm-
boendarterectomy procedure when the child was 6 months
old. In the report by Petäjä and colleagues, the authors stud-
ied the effect of routine transfusion of antithrombin III con-
centrate when the measured level in neonates in the early
postoperative period was less than 50% of the adult mean.
The authors have calculated that the cost of this protocol in
Finland is $8000 in US currency per avoided case of central
venous thrombosis. In their previous report in the Journal
(1996;112:883-9; Central Venous Thrombosis After Cardiac
Operations in Children), the authors commented that in the
20 neonates and young infants whom they identified as hav-
ing had a central venous thrombosis, “anatomic correlation
between catheter and thrombus location is evident; 10
patients had thrombosis at the site of the catheter tip and/or
along the catheter route. Even in the rest of the patients the
catheter and thrombi were close enough to each other to make
a triggering effect of the catheter highly likely.”
My own observations regarding central venous thrombosis
in neonates and young infants have been identical to those of
the authors, namely, that this phenomenon is almost always
secondary to placement of either an internal jugular or sub-
clavian line. My response to this observation, however, has
been different from that of the authors. My colleagues and I
now simply avoid placement of such lines other than in very
unusual circumstances. A neonate or young infant is unlikely
to be undergoing reoperative surgery, so that major hemor-
rhage and therefore need for massive transfusion before the
heart is fully exposed should essentially never occur. At the
end of the procedure, we place a right atrial line through the
right atrial appendage, bringing the line out through the chest
wall to allow central access and monitoring of right atrial
pressure. This is a routine that we have practiced for many
years. A previous report has confirmed the minimal risk of
these catheters, which can be readily maintained for access
and monitoring for between 1 and 2 weeks before the risk of
sepsis becomes unacceptable.1 If a central line must be
placed at that time, careful attention must be paid to using as
narrow gauge a catheter as is reasonable for the purpose of
the catheter and for the size of the child, as well as appropri-
ate heparinization of the fluids being infused through the line.
Perhaps antithrombin III monitoring described by Petäjä and
colleagues would also be cost-effective in such patients.
In conclusion, I believe very strongly that there is no place
for routine placement of internal jugular and subclavian lines
in neonates and young infants undergoing cardiac surgery.
This philosophy, without question, results in a very much
lower incidence of the very debilitating complication of cen-
tral venous thrombosis in the neonate and young infant.
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